-
公开(公告)号:US09051363B2
公开(公告)日:2015-06-09
申请号:US11842042
申请日:2007-08-20
IPC分类号: A61K39/395 , C07K16/18 , A61K9/48 , A61K31/00 , A61K31/739 , A61K38/19 , A61K47/48 , C07K14/47 , A61K9/00 , A61K9/20 , A61K9/70 , A61K39/00
CPC分类号: C07K16/18 , A61K9/0019 , A61K9/2009 , A61K9/2031 , A61K9/2054 , A61K9/4866 , A61K9/7023 , A61K31/00 , A61K31/739 , A61K38/193 , A61K39/00 , A61K39/0007 , A61K39/3955 , A61K47/646 , A61K2039/505 , A61K2039/53 , A61K2039/55505 , A61K2039/55555 , A61K2039/55566 , A61K2039/55572 , A61K2039/55577 , A61K2039/6037 , A61K2039/605 , C07K14/4711 , C07K2317/24 , C07K2317/34 , C07K2317/565 , C07K2317/567 , C07K2317/77 , C07K2317/92 , C07K2319/00 , A61K2300/00
摘要: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Preferred agents include humanized antibodies.
摘要翻译: 本发明提供用于治疗与淀粉样蛋白沉积相关的疾病的改进剂和方法。 在病人的大脑中。 优选的试剂包括人源化抗体。
-
公开(公告)号:US07429644B2
公开(公告)日:2008-09-30
申请号:US10412406
申请日:2003-04-10
申请人: Ellen Garber , Paul Lyne , Jose William Saldanha
发明人: Ellen Garber , Paul Lyne , Jose William Saldanha
IPC分类号: C12P21/08 , C07K16/00 , A61K39/395 , C12P21/04 , C07H21/04
CPC分类号: C07K16/2866 , A61K2039/505 , C07K2317/24
摘要: Humanized antibodies to LT-β-R and methods of use thereof are provided.
摘要翻译: 提供了对LT-β-R的人源化抗体及其使用方法。
-
公开(公告)号:US07189819B2
公开(公告)日:2007-03-13
申请号:US10010942
申请日:2001-12-06
申请人: Guriq Basi , Jose William Saldanha
发明人: Guriq Basi , Jose William Saldanha
IPC分类号: C07K16/18 , A61K39/395 , C12P21/08
CPC分类号: C07K16/18 , A61K38/1709 , A61K38/193 , A61K39/00 , A61K39/0007 , A61K2039/505 , A61K2039/53 , A61K2039/55505 , A61K2039/55566 , A61K2039/55572 , A61K2039/55577 , C07K14/4711 , C07K2317/24 , C07K2317/567 , C07K2317/77 , C07K2319/00 , A61K2300/00
摘要: The invention provides improves agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Preferred agents include humanized antibodies.
摘要翻译: 本发明提供用于治疗与患者脑中Aβ的淀粉样蛋白沉积相关的疾病的改进剂和方法。 优选的试剂包括人源化抗体。
-
公开(公告)号:US07179892B2
公开(公告)日:2007-02-20
申请号:US10388389
申请日:2003-03-12
申请人: Guriq Basi , Jose William Saldanha
发明人: Guriq Basi , Jose William Saldanha
IPC分类号: C07K16/18 , A61K39/395 , C12P21/08
CPC分类号: C07K16/18 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C12N2510/02
摘要: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Preferred agents include humanized antibodies.
-
公开(公告)号:US5817790A
公开(公告)日:1998-10-06
申请号:US436717
申请日:1995-05-08
申请人: Masayuki Tsuchiya , Koh Sato , Mary Margaret Bendig , Steven Tarran Jones , Jose William Saldanha
发明人: Masayuki Tsuchiya , Koh Sato , Mary Margaret Bendig , Steven Tarran Jones , Jose William Saldanha
IPC分类号: C12N15/09 , A61K38/00 , A61K39/395 , A61P35/00 , C07K16/18 , C07K16/24 , C07K16/26 , C07K16/28 , C07K19/00 , C12N5/10 , C12N15/13 , C12P21/08 , C12R1/91 , G01N33/53 , G01N33/577 , C07H21/04
CPC分类号: C07K16/2866 , A61K38/00 , C07K2317/24 , C07K2319/00
摘要: A reshaped human antibody to the human IL-6R, comprising: (A) an L chain comprising, (1) a human L chain C region, and (2) an L chain V region comprising human L chain framework regions (FRs), and mouse L chain complementary determination regions (CDRs) of a monoclonal antibody to the IL-6 receptor (IL-6R); and (B) an H chain comprising, (1) a human H chain C region, and (2) an H chain V region comprising human H chain FRs, and mouse H chain CDRs of a monoclonal antibody to the IL-6R. Since major portion of the reshaped human antibody is derived from a human antibody and the mouse CDRs which are less immunogenic, the present reshaped human antibody is less immunogenic to human, and therefor is promised for therapeutic uses.
摘要翻译: 对人IL-6R的重构人抗体包含:(A)包含(1)人L链C区的L链,和(2)包含人L链框架区(FR)的L链V区, 和IL-6受体(IL-6R)的单克隆抗体的小鼠L链互补决定区(CDR); 和(B)包含(1)人H链C区的H链和(2)包含人H链FR的H链V区和IL-6R单克隆抗体的小鼠H链CDR。 由于重构的人抗体的大部分衍生自人抗体和免疫原性较小的小鼠CDR,所以本发明的重组人抗体对人的免疫原性较低,因此被用于治疗用途。
-
公开(公告)号:US5795965A
公开(公告)日:1998-08-18
申请号:US137117
申请日:1993-12-20
申请人: Masayuki Tsuchiya , Koh Sato , Mary Margaret Bendig , Steven Tarran Jones , Jose William Saldanha
发明人: Masayuki Tsuchiya , Koh Sato , Mary Margaret Bendig , Steven Tarran Jones , Jose William Saldanha
IPC分类号: C12N15/09 , A61K38/00 , A61K39/395 , A61P35/00 , C07K16/18 , C07K16/24 , C07K16/26 , C07K16/28 , C07K19/00 , C12N5/10 , C12N15/13 , C12P21/08 , C12R1/91 , G01N33/53 , G01N33/577 , C07K16/00
CPC分类号: C07K16/2866 , A61K38/00 , C07K2317/24 , C07K2319/00
摘要: A reshaped human antibody to the human IL-6R, comprising: (A) an L chain comprising, (1) a human L chain C region, and (2) an L chain V region comprising human L chain framework regions (FRs), and mouse L chain complementary determination regions (CDRS) of a momoclonal antibody to the IL-6 receptor (IL-6R); and (B) an H chain comprising, (1) a human H chain C region, and (2) an H chain V region comprising human H chain FRs, and mouse H chain CDRs of a monoclonal antibody to the IL-6R. Since major portion of the reshaped human antibody is derived from a human antibody and the mouse CDRs which are less immunogenic, the present reshaped human antibody is less immunogenic to human, and therefor is promised for therapeutic uses.
摘要翻译: PCT No.PCT / JP92 / 00544 Sec。 371日期:1993年12月20日 102(e)日期1993年12月20日PCT提交1992年4月24日PCT公布。 WO92 / 19759 PCT公开号 日期:1992年11月12日,对人IL-6R重整人抗体,其包含:(A)包含(1)人L链C区的L链,(2)包含人L链骨架的L链V区 区域(FR)和IL-6受体(IL-6R)的单克隆抗体的小鼠L链互补决定区(CDRS); 和(B)包含(1)人H链C区的H链和(2)包含人H链FR的H链V区和IL-6R单克隆抗体的小鼠H链CDR。 由于重构的人抗体的大部分衍生自人抗体和免疫原性较小的小鼠CDR,所以本发明的重组人抗体对人的免疫原性较低,因此被用于治疗用途。
-
公开(公告)号:US08084028B2
公开(公告)日:2011-12-27
申请号:US13017919
申请日:2011-01-31
IPC分类号: A61K39/395
CPC分类号: C07K16/2842 , A61K2039/505 , C07K2299/00 , C07K2317/24 , C07K2317/34 , C07K2317/51 , C07K2317/515 , C07K2317/56 , C07K2317/565 , Y02A90/26
摘要: Antibodies that specifically bind to VLA-1 integrin and methods of using these antibodies to treat immunological disorders in a subject. Also included are crystal structures of complexes formed by VLA-1 antibodies and their ligands, and VLA-1 antagonists and agonists identified by using the structure coordinates of these structures.
摘要翻译: 特异性结合VLA-1整联蛋白的抗体以及使用这些抗体治疗受试者的免疫学障碍的方法。 还包括由VLA-1抗体及其配体形成的复合物的晶体结构,以及通过使用这些结构的结构坐标鉴定的VLA-1拮抗剂和激动剂。
-
公开(公告)号:US20110189177A1
公开(公告)日:2011-08-04
申请号:US13017919
申请日:2011-01-31
CPC分类号: C07K16/2842 , A61K2039/505 , C07K2299/00 , C07K2317/24 , C07K2317/34 , C07K2317/51 , C07K2317/515 , C07K2317/56 , C07K2317/565 , Y02A90/26
摘要: Antibodies that specifically bind to VLA-1 integrin and methods of using these antibodies to treat immunological disorders in a subject. Also included are crystal structures of complexes formed by VLA-1 antibodies and their ligands, and VLA-1 antagonists and agonists identified by using the structure coordinates of these structures.
摘要翻译: 特异性结合VLA-1整联蛋白的抗体以及使用这些抗体治疗受试者的免疫学障碍的方法。 还包括由VLA-1抗体及其配体形成的复合物的晶体结构,以及通过使用这些结构的结构坐标鉴定的VLA-1拮抗剂和激动剂。
-
公开(公告)号:US20080281082A1
公开(公告)日:2008-11-13
申请号:US11842056
申请日:2007-08-20
IPC分类号: C07K16/18
CPC分类号: C07K16/18 , A61K9/0019 , A61K9/2009 , A61K9/2031 , A61K9/2054 , A61K9/4866 , A61K9/7023 , A61K31/00 , A61K31/739 , A61K38/193 , A61K39/00 , A61K39/0007 , A61K39/3955 , A61K47/646 , A61K2039/505 , A61K2039/53 , A61K2039/55505 , A61K2039/55555 , A61K2039/55566 , A61K2039/55572 , A61K2039/55577 , A61K2039/6037 , A61K2039/605 , C07K14/4711 , C07K2317/24 , C07K2317/34 , C07K2317/565 , C07K2317/567 , C07K2317/77 , C07K2317/92 , C07K2319/00 , A61K2300/00
摘要: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Preferred agents include humanized antibodies.
-
公开(公告)号:US06455677B1
公开(公告)日:2002-09-24
申请号:US09301593
申请日:1999-04-29
申请人: John Edward Park , Pilar Garin-Chesa , Uwe Bamberger , Wolfgang J. Rettig , Olivier Lèger , Jose William Saldanha
发明人: John Edward Park , Pilar Garin-Chesa , Uwe Bamberger , Wolfgang J. Rettig , Olivier Lèger , Jose William Saldanha
IPC分类号: C07K1630
CPC分类号: C07K16/40 , A61K38/00 , A61K2039/505 , C07K2317/24 , C07K2317/567 , C07K2319/00 , C12N2799/026
摘要: Recombinant antibody proteins are provided that specifically bind fibroblast activation protein alpha (FAP&agr;) and comprise framework modifications resulting in the improved producibility in host cells. The invention also relates to the use of said antibodies for diagnostic and therapeutic purposes and methods of producing said antibodies.
摘要翻译: 提供重组抗体蛋白质,其特异性结合成纤维细胞活化蛋白α(FAPalpha)并且包含框架修饰,导致提高宿主细胞的生产性。 本发明还涉及所述抗体用于诊断和治疗目的的用途以及产生所述抗体的方法。
-
-
-
-
-
-
-
-
-